Related Experiment Video
Updated: Jul 10, 2026
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Practical considerations in converting from plasma-derived to recombinant hepatitis B vaccines
1Department of Paediatrics, National Taiwan University Hospital, Taipei, Taiwan. pinging@ha.mc.ntu.edu.tw
Summary
Hepatitis B vaccines, both plasma-derived and recombinant, offer excellent safety and protection for 5-10 years. The recombinant vaccine is expected to replace the plasma-derived version due to production challenges and safety concerns.
Area of Science:
- Vaccinology
- Virology
- Immunology
Background:
- Hepatitis B virus (HBV) infection prevention relies on plasma-derived and recombinant vaccines.
- Both vaccine types demonstrate high safety, immunogenicity, and protective efficacy.
- Protection lasts 5-10 years, typically negating the need for booster doses within this period.
Purpose of the Study:
- To compare the characteristics of plasma-derived and recombinant hepatitis B vaccines.
- To discuss the future trajectory of hepatitis B vaccine development and implementation.
- To address challenges and propose solutions for ongoing hepatitis B prevention strategies.
Main Methods:
- Comparative analysis of vaccine safety, immunogenicity, and efficacy data.
- Evaluation of production costs and supply chain considerations for plasma-derived vaccines.
- Review of current literature on hepatitis B vaccine performance and future research directions.
Main Results:
- Both plasma-derived and recombinant vaccines are safe and effective, providing long-term protection.
- Plasma-derived vaccines face challenges related to production cost, plasma supply, and public perception of safety.
- Recombinant vaccines are poised to become the standard due to their advantages.
Conclusions:
- The recombinant hepatitis B vaccine is likely to supersede the plasma-derived vaccine.
- Future vaccine development should focus on enhancing immunogenicity (e.g., pre-S products), managing escape mutants, and creating combination vaccines.
- Combined vaccination strategies can improve immunization coverage and reduce the number of injections required.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...